LungLife AI Inc.
Company Snapshot
Company Overview
LungLife AI (formerly known as Cynvenio Biosystems) was founded as a spin-out from the University of California, Santa Barbara. The company is developing and commercializing cancer diagnostics by using artificial intelligence (AI)-enabled molecular analysis of cancer biomarkers, including CTCs, in blood.
The company’s focus is on lung cancer diagnostics. LungLife AI’s LungLB test is a liquid biopsy for early-stage diagnosis to confirm for clinicians whether to refer onto tissue biopsy where the LDCT Scan reveals suspicious nodules.
LungLife IA is also developing a series of companion diagnostics that are designed for later stage treatment selection as well as patient stratification in clinical trial research.
In December 2020, LungLife AI received CLIA certification for its cancer diagnostics laboratory in California. This was a key step in commercializing the company’s LungLB early-stage lung cancer liquid biopsy test.
Financial Highlights (FY 2023)
This information is available for BCC Research members only.
LungLife AI Inc. In News
Company's Business Segments
- Products : The LungLB, Others
- Services : Testing Services, Cancer Monitoring Services, Consultative Support, Others
Applications/End User Industries
- Healthcare
- Medical Research Institutes
